| View |
|
BR-725
|
Hepatitis B Vaccine (Recombinant DNA)
|
Revac-B Mcf
|
10 mcg/0.5 mL
|
Suspension For Injection (IM)
|
-
|
Bharat Biotech International Limited
|
India
|
Renewal (Revalidation)
|
18 January 2023
|
14 April 2025
|
| View |
|
BR-727
|
Pneumococcal Vaccine, Polyvalent
|
Pneumovax 23
|
25mcg/0.5mL
|
Solution For Injection (I.M./ S.C.)
|
-
|
Merck Sharp & Dohme Corp.
|
U.S.A.
|
-
|
19 October 2020
|
20 April 2025
|
| View |
|
BR-733
|
Human Normal Immunoglobulin (IVIg)
|
Gamunex-C
|
10% (100 mg/mL)
|
Solution for Infusion (IV/SC)
|
-
|
Grifols Therapeutics LLC
|
U.S.A
|
-
|
27 April 2022
|
26 May 2027
|
| View |
|
BR-734
|
Epoeitin Alfa
|
Hemapo
|
10,000 IU/mL
|
Solution for Injection (IV/SC)
|
-
|
Center of Molecular Immunology (CIM)
|
Cuba
|
Renewal (Reconstruction)
|
17 June 2022
|
29 October 2024
|
| View |
|
BR-735
|
Epoeitin Alfa
|
Hemapo
|
4000 IU/mL
|
Solution for Injection (IV/SC)
|
-
|
Center of Molecular Immunology (CIM)
|
Cuba
|
Renewal (Reconstruction)
|
17 June 2022
|
29 October 2024
|
| View |
|
BR-737
|
Diphtheria and Tetanus Vaccine (Adsorbed)
|
SII TD-VAC
|
Formulation: Each dose (0.5 mL) contains: Diphtheria Toxoid.........<5 Lf 2 2 IU) Tetanus Toxoid................<5 Lf( 40 IU) Adsorbed on Aluminum Phosphate, Al3+.....................< 1.25 mg
|
Suspension for Injection (IM)
|
-
|
Serum Institute of India Pvt. Ltd.
|
India
|
Renewal
|
02 June 2022
|
27 April 2027
|
| View |
|
BR-738
|
Bevacizumab
|
Avastin
|
100 mg/ 4 mL (25 mg/ mL)
|
Concentrate For Solution For IV Injection
|
-
|
Roche Diagnostics GmbH
|
Germany
|
-
|
08 March 2021
|
09 July 2025
|
| View |
|
BR-739
|
Bevacizumab
|
Avastin
|
400 mg/16 mL (25 mg/mL)
|
Concentrate for Solution
for Infusion (IV)
|
-
|
Roche Diagnostics GmbH
|
Germany
|
-
|
21 January 2022
|
09 July 2025
|
| View |
|
BR-740
|
Somatropin
|
Genheal
|
4 IU (equivalent to 1.6 mg)
|
Lyophilized Powder for
Injection (IM/SC)
|
-
|
Shanghai United Cell Biotechnology Co., Ltd.
|
China
|
Renewal (Revalidation)
|
17 October 2022
|
26 July 2025
|
| View |
|
BR-744
|
Recombinant Hepatitis B Vaccine
|
Engerix B
|
20 mcg/mL
|
Suspension for Injection (IM)-Thiomersal Free
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
Initial (Variation)
|
28 June 2024
|
28 June 2029
|
| View |
|
BR-745
|
Recombinant Hepatitis B Vaccine
|
Engerix B Junior
|
10 mcg/0.5 mL
|
Suspension for Injection (IM)
|
Vaccines
|
GlaxoSmithKline Biologicals NL DER SmithKline
Beecham Pharma GmbH & Co. KG
|
Germany
|
Initial (Variation)
|
22 April 2024
|
22 April 2029
|
| View |
|
BR-746
|
Filgastrim
|
Leucogen
|
300mcg/mL
|
Solution For Iv/Sc Injection
|
-
|
Center for Molecular Immunology (CIM)
|
Cuba
|
-
|
17 February 2021
|
04 August 2025
|
| View |
|
BR-747
|
Human Albumin
|
Albiomin
|
20% (200 g/L)
|
Solution for Injection for IV Infusion
|
-
|
Biotest Pharma GmbH
|
Germany
|
-
|
19 February 2021
|
07 September 2025
|
| View |
BR-749_PI_01.pdf
|
BR-749
|
Thyrotropin Alfa
|
Thyrogen
|
900 mcg
|
Lyophilized Powder For Solution For Im Injection
|
Hormone Replacement Therapy
|
Genzyme Ireland Ltd.
|
Ireland
|
Monitored Release (Compliance)
|
02 March 2018
|
02 March 2025
|
| View |
|
BR-750
|
Meningococcal (Groups A,
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
|
Menactra
|
Solution for Injection (IM) (see formulation on the
reverse side)
|
Solution For Im Injection
|
-
|
Sanofi Pasteur
|
U.S.A.
|
Renewal
|
10 July 2023
|
25 August 2028
|
| View |
|
BR-754
|
Epoetin Alfa
|
Eposino
|
6,000 IU/mL
|
Solution for Injection (IV/SC)
|
Antianemic Preparations
|
Shandong Kexing Bioproducts Co., Ltd.
|
China
|
Renewal
|
11 November 2021
|
18 October 2025
|
| View |
|
BR-755
|
Epoetin Alfa (Recombinant Human Erythropoietin)
|
Eposino
|
2,000 IU/mL
|
Solution for Injection (IV/SC)
|
-
|
Shandong Kexing Bioproducts Co., Ltd.
|
China
|
-
|
08 March 2021
|
18 October 2025
|
| View |
|
BR-756
|
Epoetin alfa
|
Eposino
|
4,000 IU/mL
|
Solution For Injection (IV/SC)
|
-
|
Shandong Kexing Bioproducts Co., Ltd.
|
China
|
-
|
11 November 2021
|
18 October 2025
|
| View |
|
BR-76
|
Albumin
|
Plasbumin - 25
|
12.5 g/50 mL (25%)
|
Solution for Injection (IV)
|
-
|
Grifols Therapeutics LLC
|
U.S.A.
|
-
|
12 May 2021
|
09 November 2025
|
| View |
|
BR-769
|
Interferon Alfa-2B (Human)
|
Shaferon
|
6 million I.U./mL
|
Solution For Injection (I.M./S.C.)
|
Immunostimulant
|
Beijing Kawin Technology Share- Holding Co., Ltd.
|
China
|
Renewal
|
29 April 2021
|
19 November 2025
|